AU2013327501B2 - Treating vascular disease and complications thereof - Google Patents

Treating vascular disease and complications thereof Download PDF

Info

Publication number
AU2013327501B2
AU2013327501B2 AU2013327501A AU2013327501A AU2013327501B2 AU 2013327501 B2 AU2013327501 B2 AU 2013327501B2 AU 2013327501 A AU2013327501 A AU 2013327501A AU 2013327501 A AU2013327501 A AU 2013327501A AU 2013327501 B2 AU2013327501 B2 AU 2013327501B2
Authority
AU
Australia
Prior art keywords
subject
chance
antibody
expected
blood vessel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013327501A
Other languages
English (en)
Other versions
AU2013327501A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xbiotech Inc
Original Assignee
Xbiotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech Inc filed Critical Xbiotech Inc
Publication of AU2013327501A1 publication Critical patent/AU2013327501A1/en
Application granted granted Critical
Publication of AU2013327501B2 publication Critical patent/AU2013327501B2/en
Assigned to XBIOTECH INC. reassignment XBIOTECH INC. Request to Amend Deed and Register Assignors: XBIOTECH, INC.
Assigned to JANSSEN BIOTECH, INC. reassignment JANSSEN BIOTECH, INC. Request for Assignment Assignors: XBIOTECH INC.
Assigned to XBIOTECH INC. reassignment XBIOTECH INC. Request for Assignment Assignors: JANSSEN BIOTECH, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2013327501A 2012-10-04 2013-10-01 Treating vascular disease and complications thereof Active AU2013327501B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
US61/709,754 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (2)

Publication Number Publication Date
AU2013327501A1 AU2013327501A1 (en) 2015-04-02
AU2013327501B2 true AU2013327501B2 (en) 2018-08-09

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013327501A Active AU2013327501B2 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Country Status (12)

Country Link
US (3) US20140099321A1 (cg-RX-API-DMAC10.html)
EP (3) EP2904010A4 (cg-RX-API-DMAC10.html)
JP (1) JP6460993B2 (cg-RX-API-DMAC10.html)
KR (2) KR102429919B1 (cg-RX-API-DMAC10.html)
CN (2) CN104684929A (cg-RX-API-DMAC10.html)
AU (1) AU2013327501B2 (cg-RX-API-DMAC10.html)
CA (1) CA2886747C (cg-RX-API-DMAC10.html)
HK (1) HK1211960A1 (cg-RX-API-DMAC10.html)
IL (1) IL237765B (cg-RX-API-DMAC10.html)
MX (1) MX376241B (cg-RX-API-DMAC10.html)
RU (1) RU2671955C2 (cg-RX-API-DMAC10.html)
WO (1) WO2014055544A1 (cg-RX-API-DMAC10.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102946904A (zh) 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
PH12013500316A1 (en) 2010-08-23 2016-09-02 Janssen Biotech Inc Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
PT2750709T (pt) 2011-09-23 2018-11-22 Xbiotech Inc Tratamento da caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
JP7145162B2 (ja) 2017-02-16 2022-09-30 ヤンセン バイオテク，インコーポレイテッド 化膿性汗腺炎の処置
AU2020267329B2 (en) * 2019-05-03 2026-03-26 University Of Zurich Treatment of brain ischemia-reperfusion injury
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
WO2000071753A2 (en) * 1999-05-24 2000-11-30 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
HUE029003T2 (en) * 2008-05-30 2017-01-30 Xbiotech Inc IL-1 alpha antibodies
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia

Also Published As

Publication number Publication date
CN113018431A (zh) 2021-06-25
EP2904010A1 (en) 2015-08-12
AU2013327501A1 (en) 2015-04-02
WO2014055544A1 (en) 2014-04-10
EP3524621A1 (en) 2019-08-14
MX2015004286A (es) 2015-08-06
MX376241B (es) 2025-03-06
CA2886747C (en) 2023-12-05
US20180057585A1 (en) 2018-03-01
JP2015531397A (ja) 2015-11-02
EP4628162A3 (en) 2025-12-03
KR20150063076A (ko) 2015-06-08
JP6460993B2 (ja) 2019-01-30
KR102296017B1 (ko) 2021-09-01
US20210403548A1 (en) 2021-12-30
IL237765B (en) 2019-06-30
US20140099321A1 (en) 2014-04-10
CA2886747A1 (en) 2014-04-10
EP2904010A4 (en) 2016-06-01
EP4628162A2 (en) 2025-10-08
RU2671955C2 (ru) 2018-11-08
CN104684929A (zh) 2015-06-03
KR102429919B1 (ko) 2022-08-05
IL237765A0 (en) 2015-05-31
RU2015110635A (ru) 2016-11-27
HK1211960A1 (en) 2016-06-03
KR20210108496A (ko) 2021-09-02

Similar Documents

Publication Publication Date Title
CA2886747C (en) Treating vascular disease and complications thereof
US12116405B2 (en) Arthritis treatment
CA2849710C (en) Cachexia treatment
CA2831126C (en) Treatment of dermatological pathologies
AU2013327498A1 (en) Treatment of psychiatric conditions
HK40130815A (en) Treating vascular disease and complications thereof
HK40012735A (en) Treating vascular disease and complications thereof
HK40053657A (en) Treating vascular disease and complications thereof
AU2017200039B2 (en) Arthritis treatment
JP2022531328A (ja) 脳虚血再灌流傷害の治療

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: XBIOTECH INC.

Free format text: FORMER NAME(S): XBIOTECH, INC.

PC Assignment registered

Owner name: JANSSEN BIOTECH, INC.

Free format text: FORMER OWNER(S): XBIOTECH INC.

PC Assignment registered

Owner name: XBIOTECH INC.

Free format text: FORMER OWNER(S): JANSSEN BIOTECH, INC.